Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.44 |
| ▸ | EPOR | P19235 | 5/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | MMP1 | P03956 | 1/20 | 0.41 |
| ▸ | MMP3 | P08254 | 1/20 | 0.41 |
| ▸ | MMP9 | P14780 | 1/20 | 0.41 |
| ▸ | KLK7 | P49862 | 2/20 | 0.41 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.41 |
| ▸ | SYK | P43405 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5066754 | 0.93 | SYK (0.45) | MAPTSIRT5MEN1KMT2AMMP1 | |
| SCHEMBL1024580 | 0.88 | MMP1 (0.44) | MAPTMEN1KMT2AMMP1MMP3 | |
| SCHEMBL1020939 | 0.88 | MEN1 (0.51) | MAPTEPORMEN1KMT2AMMP1 | |
| SCHEMBL4850221 | 0.87 | SYK (0.49) | MAPTMEN1KMT2AMMP1MMP3 | |
| SCHEMBL4850228 | 0.87 | SYK (0.49) | MAPTMEN1KMT2AMMP1MMP3 | |
| SCHEMBL1022382 | 0.85 | MMP1 (0.43) | MAPTMEN1KMT2AMMP1MMP3 | |
| SCHEMBL1021128 | 0.83 | SIRT5 (0.45) | MAPTSIRT5MEN1KMT2AMMP1 | |
| SCHEMBL1022884 | 0.82 | CTSK (0.53) | MEN1KMT2AMMP1MMP3MMP9 | |
| SCHEMBL1024008 | 0.81 | KMT2A (0.48) | MAPTMEN1KMT2AMMP1MMP3 | |
| SCHEMBL4853602 | 0.81 | SYK (0.47) | MAPTSIRT5MEN1KMT2AMMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1797110-B1 | ANTIBACTERIAL AMIDE MACROCYCLES IV | AICURIS GMBH & CO KG (DE) | 2011-01-12 | — | — | EP | disclosed |
| US-7446102-B2 | Antibacterial amide macrocycles IV | AICURIS GMBH & CO. KG (DE) | 2008-11-04 | — | — | US | disclosed |
| US-20080076745-A1 | ANTIBACTERIAL AMIDE MACROCYCLES IV | AICURIS GMBH & CO. KG (DE) | 2008-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076745-A1 | ANTIBACTERIAL AMIDE MACROCYCLES IV | NOD2, AAAS, AADAC | MAPT 4356/4885SIRT5 76/4885EPOR 1089/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.